Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Heidelberg, Australia Clinical Trials

A listing of Heidelberg, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (697) clinical trials

An Investigational Study to Evaluate BMS-986165 in Patients With Systemic Lupus Erythematosus

This study will investigate BMS-986165 to assess its effects in patients with systemic lupus erythematosus (SLE).

Phase

0.0 miles

Learn More »

DNS-3379 vs. Placebo in Stroke Rehabilitation

This is a randomized, double-blind, placebo-controlled parallel group outpatient 42-day treatment study that will utilize standard stroke rehabilitation outcome measures to evaluate the effect of DNS-3379 on upper extremity motor recovery in subjects following ischemic stroke.

Phase

0.0 miles

Learn More »

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

The study will capture post-marketing safety data on patients treated with eculizumab. Additionally, the study will collect information on the progression of disease in all patients.

Phase N/A

0.0 miles

Learn More »

A Multinational Randomized Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

The primary objective of the study is to compare overall survival of patients randomized to receiving custirsen in combination with docetaxel (Arm A) with patients randomized to receive docetaxel alone (Arm B).

Phase

0.0 miles

Learn More »

A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.

Phase N/A

0.0 miles

Learn More »

Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers

Aspirin in patients with dukes C or high risk dukes B colorectal cancer can improve survival in this patient population over placebo control. Eligible patients will be randomized to treatment arms, using the following stratification factors Study Centre Tumour Type Type of adjuvant chemotherapy received(exposed/not exposed to oxaliplatin Patients will ...

Phase

0.0 miles

Learn More »

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

This is a two-part, multicenter, double-blind, parallel-group, placebo controlled study to evaluate the effect of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with Lennox-Gastaut syndrome (LGS).

Phase

0.0 miles

Learn More »

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer

The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy alone in treating patients with previously untreated inoperable or metastatic urothelial cancer.

Phase

0.0 miles

Learn More »

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).

Phase

0.0 miles

Learn More »

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks.

Phase

0.0 miles

Learn More »